



EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Capital Increase

Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share

16-Sep-2025 / 15:22 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Ad hoc announcement

Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share

Korneuburg, September 16, 2025 - Marinomed Biotech AG (the "Company") announces that the Management Board has resolved today to increase the Company's share capital by EUR 61.607 to EUR 1.839.940 by issuing 61.607 new no-par value bearer shares against cash contributions. The new shares will be issued from the authorized capital 2024/II and are subject to the direct exclusion of the statutory subscription rights of existing shareholders. The issue price per new share is EUR 17,50 so that the total issue price amounts to EUR 1,078,123. The Company's Supervisory Board approved this capital increase today, immediately after the Management Board passed the resolution. All 61.607 new shares have been subscribed at these issue terms and conditions by a total of nine investors.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: <https://www.marinomed.com>.

For further inquiries contact:

Marinomed Biotech AG

PR: Luca Horinek

IR.: Tobias Meister

T: +43 2262 90300 158

E-Mail: pr@marinomed.com

E-Mail: ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

End of Inside Information

16-Sep-2025 CET/CEST News transmitted by EQS Group. www.eqs.com

Language:	English
Company:	Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria
Phone:	+43 2262 90300
E-mail:	office@marinomed.com
Internet:	www.marinomed.com
ISIN:	ATMARINOMED6

WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart,
Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 2198258

End of Announcement

EQS News Service